Related Experiment Video
Updated: Jan 28, 2026

A Strategy to Identify de Novo Mutations in Common Disorders such as Autism and Schizophrenia
Published on: June 15, 2011
A multitargeted probe-based strategy to identify signaling vulnerabilities in cancers
Suman Rao1, Guangyan Du2, Marc Hafner3
1Laboratory of Systems Pharmacology, Boston, Massachusetts 02115; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 02115.
Abstract:
Most cancer cells are dependent on a network of deregulated signaling pathways for survival and are insensitive, or rapidly evolve resistance, to selective inhibitors aimed at a single target. For these reasons, drugs that target more than one protein (polypharmacology) can be clinically advantageous. The discovery of useful polypharmacology remains serendipitous and is challenging to characterize and validate. In this study, we developed a non-genetic strategy for the identification of pathways that drive cancer cell proliferation and represent exploitable signaling vulnerabilities. Our approach is based on using a multitargeted kinase inhibitor, SM1-71, as a tool compound to identify combinations of targets whose simultaneous inhibition elicits a potent cytotoxic effect. As a proof of concept, we applied this approach to a KRAS-dependent non-small cell lung cancer (NSCLC) cell line, H23-KRASG12C Using a combination of phenotypic screens, signaling analyses, and kinase inhibitors, we found that dual inhibition of MEK1/2 and insulin-like growth factor 1 receptor (IGF1R)/insulin receptor (INSR) is critical for blocking proliferation in cells. Our work supports the value of multitargeted tool compounds with well-validated polypharmacology and target space as tools to discover kinase dependences in cancer. We propose that the strategy described here is complementary to existing genetics-based approaches, generalizable to other systems, and enabling for future mechanistic and translational studies of polypharmacology in the context of signaling vulnerabilities in cancers.
Insights
This study introduces a novel non-genetic method to discover cancer vulnerabilities by using a multitargeted kinase inhibitor. Dual inhibition of MEK1/2 and IGF1R/INSR effectively blocks cancer cell proliferation, highlighting a new strategy for polypharmacology in cancer treatment.
Area of Science:
- Cancer Biology
- Pharmacology
- Molecular Signaling
Background:
- Cancer cells rely on complex signaling networks for survival, often developing resistance to single-target drugs.
- Polypharmacology, using drugs that target multiple proteins, offers clinical advantages but is difficult to discover and validate.
- Identifying exploitable signaling vulnerabilities in cancer requires innovative strategies beyond traditional genetic approaches.
Purpose of the Study:
- To develop a non-genetic strategy for identifying cancer cell proliferation drivers and exploitable signaling vulnerabilities.
- To utilize a multitargeted kinase inhibitor (SM1-71) as a tool to discover effective polypharmacology combinations.
- To validate the approach in a KRAS-dependent non-small cell lung cancer (NSCLC) cell line.
Main Methods:
- Employed a multitargeted kinase inhibitor, SM1-71, as a tool compound.
- Utilized phenotypic screens and signaling analyses to identify target combinations.
- Applied kinase inhibitors to test the efficacy of dual inhibition strategies.
Main Results:
- Identified dual inhibition of MEK1/2 and insulin-like growth factor 1 receptor (IGF1R)/insulin receptor (INSR) as critical for blocking proliferation in H23-KRASG12C NSCLC cells.
- Demonstrated the effectiveness of the non-genetic strategy in discovering a specific polypharmacology combination.
- Validated the utility of SM1-71 as a tool compound for uncovering kinase dependencies.
Conclusions:
- Multitargeted tool compounds with well-defined polypharmacology are valuable for discovering kinase dependencies in cancer.
- The described non-genetic strategy is complementary to genetic approaches and generalizable to other cancer systems.
- This approach enables future mechanistic and translational studies of polypharmacology in cancer signaling vulnerabilities.
More Related Videos
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
What is Cell Signaling?
Endocrine Signaling
Paracrine Signaling
Bacterial Signaling
Synaptic Signaling

